Tianjin Medical Journal ›› 2023, Vol. 51 ›› Issue (1): 14-18.doi: 10.11958/20220657
• Cell and Molecular Biology • Previous Articles Next Articles
ZHANG Xinyan1(), ZHAO Guodong2
Received:
2022-04-28
Revised:
2022-06-13
Published:
2023-01-15
Online:
2023-01-17
ZHANG Xinyan, ZHAO Guodong. The mechanism of miR-891a-5p regulating the biological process of colorectal cancer cells by targeting CPEB1[J]. Tianjin Medical Journal, 2023, 51(1): 14-18.
CLC Number:
组别 | miR-891a-5p | CyclinD1 | Pro-caspase-3 | |||
---|---|---|---|---|---|---|
A组 | 0.99±0.18 | 0.69±0.08 | 0.28±0.04 | |||
B组 | 1.07±0.09 | 0.65±0.07 | 0.25±0.04 | |||
C组 | 0.33±0.07a | 0.34±0.05a | 0.27±0.05 | |||
D组 | 0.35±0.06 | 0.29±0.03 | 0.24±0.03 | |||
E组 | 0.77±0.09b | 0.54±0.06b | 0.26±0.05 | |||
F | 95.611* | 79.844* | 1.236 | |||
组别 | C-caspase-3 | 增殖率(%) | 凋亡率(%) | |||
A组 | 0.15±0.04 | 100.89±10.68 | 4.16±0.84 | |||
B组 | 0.17±0.03 | 98.74±9.25 | 5.16±1.07 | |||
C组 | 0.48±0.05a | 71.64±8.17a | 17.51±2.48a | |||
D组 | 0.53±0.04 | 101.49±11.64 | 15.39±1.88 | |||
E组 | 0.33±0.05b | 148.67±12.47b | 8.43±1.12b | |||
F | 148.945* | 62.285* | 127.864* |
Tab.1 Comparison of miR-891a-5p, Cyclin D1, Pro-caspase-3 and C-caspase-3 protein expression levels and proliferation and apoptosis rates between the five groups
组别 | miR-891a-5p | CyclinD1 | Pro-caspase-3 | |||
---|---|---|---|---|---|---|
A组 | 0.99±0.18 | 0.69±0.08 | 0.28±0.04 | |||
B组 | 1.07±0.09 | 0.65±0.07 | 0.25±0.04 | |||
C组 | 0.33±0.07a | 0.34±0.05a | 0.27±0.05 | |||
D组 | 0.35±0.06 | 0.29±0.03 | 0.24±0.03 | |||
E组 | 0.77±0.09b | 0.54±0.06b | 0.26±0.05 | |||
F | 95.611* | 79.844* | 1.236 | |||
组别 | C-caspase-3 | 增殖率(%) | 凋亡率(%) | |||
A组 | 0.15±0.04 | 100.89±10.68 | 4.16±0.84 | |||
B组 | 0.17±0.03 | 98.74±9.25 | 5.16±1.07 | |||
C组 | 0.48±0.05a | 71.64±8.17a | 17.51±2.48a | |||
D组 | 0.53±0.04 | 101.49±11.64 | 15.39±1.88 | |||
E组 | 0.33±0.05b | 148.67±12.47b | 8.43±1.12b | |||
F | 148.945* | 62.285* | 127.864* |
组别 | N-cadherin | Vimentin | E-cadherin | 迁移数 (个/视野) | 侵袭数 (个/视野) |
---|---|---|---|---|---|
A组 | 0.75±0.08 | 0.63±0.06 | 0.29±0.03 | 147.94±11.84 | 84.38±8.79 |
B组 | 0.78±0.06 | 0.61±0.05 | 0.24±0.04 | 145.46±12.85 | 84.38±8.79 |
C组 | 0.43±0.05a | 0.22±0.03a | 0.58±0.08a | 61.48±5.58a | 47.76±4.64a |
D组 | 0.38±0.03 | 0.27±0.05 | 0.44±0.05 | 64.67±9.59 | 41.79±5.53 |
E组 | 0.48±0.06b | 0.63±0.07b | 0.19±0.03b | 117.95±12.92b | 66.58±6.94b |
F | 92.726* | 135.375* | 93.549* | 134.882* | 70.183* |
Tab.2 Comparison of N-cadherin, E-cadherin and Vimentin protein expression levels and migration and invasion numbers between the five groups
组别 | N-cadherin | Vimentin | E-cadherin | 迁移数 (个/视野) | 侵袭数 (个/视野) |
---|---|---|---|---|---|
A组 | 0.75±0.08 | 0.63±0.06 | 0.29±0.03 | 147.94±11.84 | 84.38±8.79 |
B组 | 0.78±0.06 | 0.61±0.05 | 0.24±0.04 | 145.46±12.85 | 84.38±8.79 |
C组 | 0.43±0.05a | 0.22±0.03a | 0.58±0.08a | 61.48±5.58a | 47.76±4.64a |
D组 | 0.38±0.03 | 0.27±0.05 | 0.44±0.05 | 64.67±9.59 | 41.79±5.53 |
E组 | 0.48±0.06b | 0.63±0.07b | 0.19±0.03b | 117.95±12.92b | 66.58±6.94b |
F | 92.726* | 135.375* | 93.549* | 134.882* | 70.183* |
组别 | WT-CPEB1 | MUT-CPEB1 | CPEB1 |
---|---|---|---|
F组 | 1.01±0.07 | 1.08±0.12 | 0.53±0.06 |
G组 | 0.62±0.07 | 1.12±0.09 | 0.27±0.03 |
t | 11.819* | 0.800 | 11.628* |
B组 | 0.95±0.09 | 1.15±0.14 | 0.59±0.06 |
C组 | 1.82±0.11 | 1.09±0.11 | 0.85±0.08 |
t | 18.364* | 1.011 | 7.800* |
Tab.3 Comparison of fluorescence activity of WT-CPEB1 and MUT-CPEB1 and CPEB1 protein expression levels between the four groups
组别 | WT-CPEB1 | MUT-CPEB1 | CPEB1 |
---|---|---|---|
F组 | 1.01±0.07 | 1.08±0.12 | 0.53±0.06 |
G组 | 0.62±0.07 | 1.12±0.09 | 0.27±0.03 |
t | 11.819* | 0.800 | 11.628* |
B组 | 0.95±0.09 | 1.15±0.14 | 0.59±0.06 |
C组 | 1.82±0.11 | 1.09±0.11 | 0.85±0.08 |
t | 18.364* | 1.011 | 7.800* |
[1] | SIEGEL R L, MILLER K D, FEDEWA S A, et al. Colorectal cancer statistics,2017[J]. CA Cancer J Clin, 2017, 67(3):177-193. doi:10.3322/caac.21395. |
[2] | WEINBERG B A, MARSHALL J L, SALEM M E. The growing challenge of young adults with colorectal cancer[J]. Oncology(Williston Park), 2017, 31(5):381-389. |
[3] | WROBEL P, AHMED S. Current status of immunotherapy in metastatic colorectal cancer[J]. Int J Colorectal Dis, 2019, 34(1):13-25. doi:10.1007/s00384-018-3202-8. |
[4] | MCCORRY A M, LOUGHREY M B, LONGLEY D B, et al. Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition[J]. J Pathol, 2018, 246(4):422-426. doi:10.1002/path.5155. |
[5] | FERRAGUT CARDOSO A P, UDOH K T, STATES J C. Arsenic-induced changes in miRNA expression in cancer and other diseases[J]. Toxicol Appl Pharmacol, 2020, 409(12):115306. doi:10.1016/j.taap.2020.115306. |
[6] | ALI SYEDA Z, LANGDEN S S S, MUNKHZUL C, et al. Regulatory mechanism of microRNA expression in cancer[J]. Int J Mol Sci, 2020, 21(5):1723. doi:10.3390/ijms21051723. |
[7] | ZHANG C, DANG D, CONG L, et al. Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis[J]. Cancer Med, 2021, 10(14):4710-4720. doi:10.1002/cam4.3963. |
[8] | HASEGAWA T, GLAVICH G J, PAHUSKI M, et al. Characterization and evidence of the miR-888 cluster as a novel cancer network in prostate[J]. Mol Cancer Res, 2018, 16(4):669-681. doi:10.1158/1541-7786.MCR-17-0321. |
[9] | KOZLOV E, SHIDLOVSKII YV, GILMUTDINOV R, et al. The role of CPEB family proteins in the nervous system function in the norm and pathology[J]. Cell Biosci, 2021, 11(1):64. doi:10.1186/s13578-021-00577-6. |
[10] | WANG H, MA Z, LIU X, et al. MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN[J]. Biomed Pharmacother, 2019, 111:1103-1111. doi:10.1016/j.biopha.2018.12.115. |
[11] | ZHANG Z, XU L, HE L, et al. MiR-891a-5p as a prognostic marker and therapeutic target for hormone receptor-positive breast cancer[J]. J Cancer, 2020, 11(13):3771-3782. doi:10.7150/jca.40750. |
[12] | WANG Y, HUANG L, SHAN N, et al. Establishing a three-miRNA signature as a prognostic model for colorectal cancer through bioinformatics analysis[J]. Aging(Albany NY), 2021, 13(15):19894-19907. doi:10.18632/aging.203400. |
[13] | WAN N, ZHENG J. MicroRNA-891a-5p is a novel biomarker for non-small cell lung cancer and targets HOXA5 to regulate tumor cell biological function[J]. Oncol Lett, 2021, 22(1):507. doi:10.3892/ol.2021.12768. |
[14] | JIA Y, ZHAO J, YANG J, et al. miR-301 regulates the SIRT1/SOX2 pathway via CPEB1 in the breast cancer progression[J]. Mol Ther Oncolytics, 2021, 22:13-26. doi:10.1016/j.omto.2021.03.007. |
[15] | ZHANG H, YANG W, YAN J, et al. Loss of profilin 2 contributes to enhanced epithelial-mesenchymal transition and metastasis of colorectal cancer[J]. Int J Oncol, 2018, 53(3):1118-1128. doi:10.3892/ijo.2018.4475. |
[16] | ZHAI D, CUI C, XIE L, et al. Sterol regulatory element-binding protein 1 cooperates with c-Myc to promote epithelial-mesenchymal transition in colorectal cancer[J]. Oncol Lett, 2018, 15(4):5959-5965. doi:10.3892/ol.2018.8058. |
[17] | WANG J, WANG T, ZHANG Y, et al. CPEB1 enhances erastin-induced ferroptosis in gastric cancer cells by suppressing twist1 expression[J]. IUBMB Life, 2021, 73(9):1180-1190. doi:10.1002/iub.2525. |
[18] | SHAO K, PU W, ZHANG J, et al. Epigenetic Repressing of CPEB1 enhances malignant progression by reducing chromatin accessibility of CEBPB in colorectal cancer[EB/OL]. (2020-04-29)[2022-04-28]. https://ssrn.com/abstract=3590453. |
[19] | SHAO K, PU W, ZHANG J, et al. DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter[J]. Clin Epigenetics, 2021, 13(1):89. doi:10.1186/s13148-021-01071-z. |
[20] | FANG Y, ZHONG Q, WANG Y, et al. CPEB3 functions as a tumor suppressor in colorectal cancer via JAK/STAT signaling[J]. Aging(Albany NY), 2020, 12(21):21404-21422. doi:10.18632/aging.103893. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||